ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
MEET THE PATIENTS WHERE THEY ARE: a new perspective on translational research in the field to accelerate precision oncology
Team members of the Judith Tam ALK Lung Cancer Research Initiative ventured out to Nashville on July 18th for the 2024 ALK Positive Summit, to embark on an unprecedented research blood collection which took place July 19th and 20th. This was the culmination of 5 months of intense visioning with ALK Positive, Inc and sculpting…
-
Matt & Stephanie McAvin
Matt and Stephanie Mcavin were recently featured in Genentech’s Biomarker Testing Campaign that was filmed during the ALK Summit in Nashville. We interviewed them about their story living with an ALK+ cancer diagnosis, juggling Matt’s diagnosis with caring for their family of three teenagers, and their advocacy in getting the word out on the importance…
-
Discovering Insights Beyond Clinical Trials: Exploring ALK-Positive Lung Cancer Treatment
Clinical trials are the gold standard for evaluating new treatments in medicine. They offer a structured approach, where patient groups are carefully selected, treatments are administered, and results are meticulously followed over time. This controlled environment allows for a deep understanding of how treatments perform in specific patient populations, free from the confounding factors that…
-
Special series on “ALK-positive NSCLC” in the Translational Lung Cancer Research (TLCR) journal.
About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to…
-
Introducing ALK Positive Australia Inc. An interview with Deputy Chairperson, Graham Hall
Can you share with our readers the founding story of the ALK Positive Australia? What inspired the establishment of the organisation. I, like many others, including the other founders, felt at initial diagnosis that it was difficult to find local, relevant information about ALK+ Lung Cancer and I was dubious of heading to Facebook for…
-
Gilteritinib for the Treatment of ALK positive non-small cell lung cancer (NSCLC)
This trial is for patients with Stage 4 ALK positive NSCLC that have progressed on an earlier generation ALK TKI AND lorlatinib, and on any number of other standard-of-care or trial treatments. The trial drug is gilteritinib (aka Xospata), which was approved by the FDA in 2018 for a type of leukemia, but has been…
-
Vegan Tuscan Chickpeas A recipe by chef and fellow ALKie, Juli Posner
When we think of Superfoods, chickpeas are not necessarily what comes to mind, but chickpeas have many surprising health benefits. They contain important vitamins and minerals (B, B6, folate and vitamin E), they have protein, lots of fiber, and all that fiber may actually keep you feel fuller longer, keeping your weight in check.They are…
-
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or…
-
Patient Spotlight Marc Muskavitch Boston area, Massachusetts, USA
Marc Muskavitch is an ALK patient, Board member for ALK Positive, Inc., and one of the leading members of the ALK Positive Medical Committee. We interviewed him on his journey with ALK+ lung cancer so far, his work with the Medical Committee, and what most excites him about the future of ALK+ cancer treatments and…
-
Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership
Break Through Cancer announces a new partnership with ALK Positive Inc. (ALK Positive), a foundation funded by patients with ALK-positive lung cancer and their families. ALK Positive and Break Through Cancer are joining forces to fund a new initiative in lung cancer research with the hope of creating durable responses and cures for patients with…
-
The Global Landscape of Research: ALK-Positive Cancer Therapeutic Trials Worldwide
In the ever-evolving arena of ALK-positive cancer therapies, clinical trials offer patients not only cutting-edge interventions but also a chance to contribute to the advancement of ALK cancer treatment. In examining international ALK cancer trials, we uncover both challenges and opportunities for those seeking innovative treatments beyond conventional options. ALK Positive is the first foundation…
-
